Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.16 USD
+0.01 (0.87%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.15 -0.01 (-0.86%) 6:50 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACRS 1.16 +0.01(0.87%)
Will ACRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRS
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Other News for ACRS
Aclaris Therapeutics’ ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment
Aclaris Therapeutics (ACRS) Gets a Hold from H.C. Wainwright
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris announces first patient dosed in Phase 2a trial of ATI-2138
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference